Document Detail


Effect of recombinant human erythropoietin in preterm infants.
MedLine Citation:
PMID:  10480285     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Twenty-five premature infants (mean gestational age+/-SD, 31.4+/-1.9 weeks) were administered subcutaneously recombinant human erythropoietin (rHuEpo) at a dose of 300 u/kg of body weight three times a week beginning on the third day of life and continuing for 6 weeks. The controls (n=23) were premature infants with a mean gestational age of 32.2+/-2.3 weeks who did not receive rHuEpo. Haematological indices, haemoglobin and serum phosphate (Pi), and red blood cell (RBC) phosphate metabolites (ATP, 2,3-DPG, RBCPi) were tested monthly until the 6th month and thereafter at the 9th and 12th months of life. The level of serum soluble transferrin receptors (sTfR) correlated significantly with rHuEpo (p<0.05). The ratio of sTfR to log (ferritin) was significantly higher (p<0.001) in the infants treated with rHuEpo than the controls. Intracellular organic and inorganic Pi changes were not affected by the Epo administration. The RBC 2,3-DPG seemed adequate in infants receiving rHuEpo.
Authors:
N Krallis; V Cholevas; A Mavridis; I Georgiou; K Bourantas; S Andronikou
Related Documents :
1155065 - Glucose tolerance and insulin secretion in very small babies.
10021725 - Immunohematological study in newborn infants with erythroblastosis fetalis transfused i...
12499575 - Development of the chymase inhibitor as an anti-tissue-remodeling drug: myocardial infa...
17032445 - Foetal and neonatal alloimmune thrombocytopaenia.
25092075 - Role of admission gas exchange measurement in predicting congenital diaphragmatic herni...
10313505 - Vaginal birth after cesarean section in an hmo.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  European journal of haematology     Volume:  63     ISSN:  0902-4441     ISO Abbreviation:  Eur. J. Haematol.     Publication Date:  1999 Aug 
Date Detail:
Created Date:  1999-09-23     Completed Date:  1999-09-23     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8703985     Medline TA:  Eur J Haematol     Country:  DENMARK    
Other Details:
Languages:  eng     Pagination:  71-6     Citation Subset:  IM    
Affiliation:
Child Health Department, Neonatology Clinic, University of Ioannina, Medical School, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
2,3-Diphosphoglycerate / blood
Adenosine Triphosphate / blood
Anemia / drug therapy,  prevention & control*
Energy Metabolism
Erythrocytes / metabolism*
Erythropoietin / blood
Erythropoietin, Recombinant / therapeutic use*
Follow-Up Studies
Gestational Age
Humans
Infant, Newborn
Infant, Premature*
Phosphates / blood*
Prospective Studies
Receptors, Transferrin / blood
Treatment Outcome
Chemical
Reg. No./Substance:
0/Erythropoietin, Recombinant; 0/Phosphates; 0/Receptors, Transferrin; 11096-26-7/Erythropoietin; 138-81-8/2,3-Diphosphoglycerate; 56-65-5/Adenosine Triphosphate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Serum mercury concentration in relation to survival, symptoms, and diseases: results from the prospe...
Next Document:  Retrospective study of candidemia in patients with hematological malignancies. Clinical features, ri...